LONDON: Moderna Inc’s vaccine candidate against the Omicron coronavirus variant will enter clinical development in the next few weeks and the company expects to be able to share data with regulators around March, CEO Stephane Bancel said on Monday.
“The vaccine is being finished, it should be in the clinic in coming weeks. We are hoping in the March timeframe to be able to have data to share with regulators to figure out next steps,” Bancel said at the World Economic Forum’s virtual Davos Agenda conference.
Moderna is also developing a single vaccine that combines a booster dose against Covid-19 with its experimental flu shot.
Bancel said the best case scenario was the combined Covid/flu vaccine would be available by the fall of 2023, at least in some countries.
“Our goal is to be able to have a single annual booster so that we don’t have compliance issues where people don’t want to get two to three shots a winter.”
Many countries are already offering a third dose of a Covid-19 vaccine to their citizens, especially to older individuals and those who are immunocompromised, while Israel has started offering its citizens a fourth dose.
Earlier in January, Moderna’s CEO said people may need a fourth shot in the fall of 2022 as the efficacy of boosters against Covid-19 was likely to decline over the next few months.
However, booster programs have met with skepticism from some disease experts over whether, and how widely, additional doses should become available, including the European Union’s drug regulator, which has expressed doubts about the need for a fourth booster dose.
Speaking at the same event, top US infectious disease expert Anthony Fauci said there was no evidence that repeat booster doses would overwhelm the immune system.
“Giving boosters at different times, there is really no evidence that’s going to hinder (immune response).”
Fauci said the goal should be to have a booster that induces a response against multiple potential variants.
- Sony CEO Hirai cleared scenes in film on N. Korea’s Kim
- Facebook CEO's 'search' comments raise hopes, questions
- How the Vietnam War made female CEOs better than men
- Aiming to sidestep Apple dispute, Obama makes case for access to device data
- Ashley Madison founder emails leaked in new data dump
- Vietnam's FPT to appoint new CEO to head global expansion
- Sony battles to regain trust after data breach
- West agrees wider Russia sanctions as Kiev says forces near crash site
- EVENTS IN HANOI, HCM CITY ON MARCH 1-15
- EVENTS SCHEDULED FOR MARCH 1-15 (daily updated)
- Real Madrid director says galactico spending may continue
- Chinese say no as MH370 to Thai coup deter trips
- More than 60,000 killed in Syria conflict, UN says
- EVENTS SCHEDULED FOR MARCH 10-20 (daily updated)
- CDC: Spray is here; swine flu shots come next week
- MF Global CEO Jon Corzine quits as big bet fails
- App-centric iPhone model is overrated: RIM CEO
- GM says recalled cars safe, but has not tested for knee-bump danger
- 'Back to drawing board' if MH370 search fails, Malaysia says
- Google’s Windows-killer takes its second shot
Moderna CEO says data for Omicron-specific shot likely available in March have 502 words, post on health.economictimes.indiatimes.com at January 18, 2022. This is cached page on Business News. If you want remove this page, please contact us.